hVIVO (LON:HVO) Shares Cross Above 50-Day Moving Average – Should You Sell?

Posted by Donna Armstrong on Feb 6th, 2026

hVIVO plc (LON:HVO – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 6.01 and traded as high as GBX 6.20. hVIVO shares last traded at GBX 6.09, with a volume of 6,746,193 shares.

Wall Street Analysts Forecast Growth

HVO has been the topic of several research reports. Peel Hunt restated an “add” rating and issued a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital reaffirmed a “buy” rating and set a GBX 25 target price on shares of hVIVO in a research note on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of GBX 17.50.

Check Out Our Latest Stock Report on hVIVO

hVIVO Stock Performance

The stock has a 50-day moving average of GBX 6.01 and a 200 day moving average of GBX 7.55. The stock has a market cap of £41.92 million, a PE ratio of 7.92 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

Insider Activity

In other news, insider Stephen Pinkerton bought 520,000 shares of hVIVO stock in a transaction on Monday, December 15th. The shares were bought at an average cost of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan bought 3,310,405 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was purchased at an average price of GBX 6 per share, for a total transaction of £198,624.30. 5.25% of the stock is currently owned by company insiders.

hVIVO Company Profile

(Get Free Report)

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.